Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Archived from the original on 29 March 2023
To be clear, none of the enrolled participants reported liver-related side effects, symptoms, or liver failure
[11] Eli Lilly and Company, 'The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)', ClinicalTrials.gov identifier NCT06383390
Retatrutide may be worth waiting for only in rare cases: patients who've maximized results on both approved options
You can track the latest updates on retatrutide availability as trials progress
In the landmark STEP 1 trial (Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding and colleagues, New England Journal of Medicine , 2021), 1,961 adults who took weekly semaglutide (2.4 mg) plus lifestyle support lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo, and 86% achieved at least 5% weight loss
US$ 26.33
US$ 28.86
US$ 20.66
US$ 27.85
US$ 24.12
US$ 21.20
US$ 26.72
US$ 27.10
